Guido Neels joined EW in 2006 and is an Operating Partner.
Mr. Neels has played a key role in building and leading EW’s medical device investment practice. He currently serves on the Board of Directors of EW growth equity portfolio companies AxoGen and Bioventus, and has been a kay member of the deal team in a number of the firm’s recent growth equity investments, including Sonendo and TELA Bio.
Prior to joining EW, Mr. Neels served as Chief Operating Officer of Guidant Corporation, a world leader in the development of cardiovascular medical products prior to the company’s acquisition for $25 billion. Mr. Neels was responsible for the global operations of Guidant’s four operating units, Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery, and Endovascular Solutions. Previously, he was responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. He also served as Vice President of Global Marketing for Vascular Intervention and as Managing Director for German and Central European operations. Prior to joining Guidant, Mr. Neels held general management, sales and marketing positions at Lilly in the U.S. and Europe.
Mr. Neels holds a Business Engineering degree from the University of Leuven in Belgium and a Master of Business Administration from Stanford University.